Abstract 248 Novel cryoballoon system for single shot pulmonary vein isolation: Frist clincial experience.

Clin Res Cardiol (2021). 10.1007/s00392-021-01933-9
Novel cryoballoon system for single shot pulmonary vein isolation: Frist clincial experience.
C.-H. Heeger¹, C. Eitel², H. L. Phan¹, N. Große¹, B. Kirstein², A. Keelani¹, K.-H. Kuck³, J. Vogler¹, R. R. Tilz¹
¹Medizinische Klinik II / Kardiologie, Angiologie, Intensivmedizin, Universitätsklinikum Schleswig-Holstein, Lübeck; ²Med. Klinik II / Kardiologie, Elektrophysiologie, Universitätsklinikum Schleswig-Holstein, Lübeck; ³Kardiologie, LANS Cardio Hamburg, Hamburg;
Background: The arctic front cryoballon (AF-CB) provides effective and durable pulmonary vein isolation (PVI) associated with encouraging clinical outcome data. The POLARx cryoballoon incorporates unique features which may translate into improved efficacy and safety. Methods: Fifty-nine consecutive patients with paroxysmal or persistent atrial fibrillation (AF) were prospectively enrolled, underwent POLARx based PVI. Safety and efficacy were assessed. Results: In 59 patients (mean age 67±5 years, 35/59, 59% paroxysmal AF) a total of 236 pulmonary veins (PV) were identified and 234/236, 99,1% PVs were successfully isolated utilizing the POLARx. The mean minimal cryoballoon temperature was -57±7°C. Real-time PVI was visualized in 83% of patients. Despite a certain learning curve utilizing the POLARx the mean procedure time 50±15 minutes. Concerning periprocedural complications 4 phrenic nerve injuries (6.8%), 1 minor bleeding (1.7%) and 1 (1.7%) transient air embolism has been observed. Conclusions: The novel POLARx shows a promising safety and efficacy profile. Further studies are necessary to draw final conclusion.
https://dgk.org/kongress_programme/ht2021/P911.htm